The Company periodically enters into agreements with certain limited specialty pharmacies and specialty distributors for the sale of XDEMVY in the U.S.
in China for the treatment of Demodex blepharitis and Meibomian Gland Disease (“MGD”) to Xi An Grand Chang An Pharmaceutical Co., Ltd. (“GrandPharma”). Revenue is recognized in proportion to the allo…
Tarsus Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
TARS-DEBT
Debt stack $88.7M
90%
Market cache reports total debt of $88.7M.
TARS-DEBT-12882
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
TARS-DEBT-12881
Warrants outstanding: 312500
90%
xbrl warrant detail from xbrl 2026-03-31.
Tarsus Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Tarsus Pharmaceuticals, Inc..
Tarsus Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
TARS-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 256 tracked holders.
Tarsus Pharmaceuticals, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
